European Pharmaceutical Review

MARCH 1, 2023

In a recent study, Massachusetts Institute of Technology (MIT) researchers developed a new purification method to cut the costs of manufacturing protein drugs. The engineers used bioconjugate-functionalised nanoparticles to quickly and inexpensively isolate proteins from a bioreactor. It separates proteins based on their size.

Vaccines 92

Vaccines 92

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

pharmaphorum

DECEMBER 23, 2022

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Inobrodib works by targeting twin cancer proteins p300 and CBP, which impacts the expression of cancer drivers including MYC and IRF4. CellCentric, a U.K-based

Immunization 52

Immunization Hospitals Vaccines 52

European Pharmaceutical Review

JULY 11, 2022

The novel coronavirus vaccine has been developed at Caltech and The University of Oxfor d. Funding of up to $30 million will support vaccine design, its development through Phase I trials and regulatory activities. . The novel vaccine, which is based on mosaic?8 How the novel coronavirus vaccine works.

Vaccines 91

Vaccines Immunization 91